<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01851512</url>
  </required_header>
  <id_info>
    <org_study_id>DA3803_HCG_I</org_study_id>
    <nct_id>NCT01851512</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803</brief_title>
  <official_title>Single-Blind, Randomized, Comparative, Phase I Study to Evaluate the Tolerability, Safety, and Pharmacokinetic Characteristics of Human Chorionic Gonadotropin Between Two Recombinant hCG Products, DA-3803 Injection and Ovidrel Liquid Injection, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-blind, randomized, comparative, phase I study to evaluate the tolerability,
      safety and pharmacokinetic characteristics of human chorionic gonadotropin between two
      recombinant hCG products named DA-3803 injection and ovidrel liquid injection, in healthy
      subjects. The subjects will injected with these two injections at the the 21day-interval of
      time and their conditions including vital signs, blood, clinical examination will be
      carefully observed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration in serum of hCG examined by non-compartmental analysis</measure>
    <time_frame>3 weeks</time_frame>
    <description>Examine the following:
Maximum blood concentration
Travel time of maximum blood concentration
half time t(1/2)
Clearance
Volume of distribution</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Infertility</condition>
  <condition>Induction of Ovulation</condition>
  <arm_group>
    <arm_group_label>T-R (Test-Reference drug)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-3803 Injection is injected first and Ovidrel liquid injection is injected after 3-week period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-T (Reference-Test drug)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ovidrel liquid injection is injected first and DA-3803 Injection is injected after 3-week period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-R (Test-Reference drug)</intervention_name>
    <arm_group_label>T-R (Test-Reference drug)</arm_group_label>
    <other_name>Drug: DA-3803 (Test drug)</other_name>
    <other_name>Drug: Ovidrel liquid injection (Referecne drug)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-T (Reference-Test drug)</intervention_name>
    <arm_group_label>R-T (Reference-Test drug)</arm_group_label>
    <other_name>Drug: Ovidrel liquid injection (Referecne drug)</other_name>
    <other_name>Drug: DA-3803 (Test drug)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No medical history relating to the alimentary system, liver system, heart system,
             haematological disease

          -  Ideal body weight +/- 20%

        Exclusion Criteria:

          -  acute disease within 28 days

          -  medical history that might affect the absorption, distribution, secretion, metabolism
             of drugs

          -  metrectomy surgery

          -  desexualization

          -  tubal ligation

          -  menopause

          -  pregnancy

          -  not able to use contraception

          -  drink alcohol more than 14 units/week

          -  smoker who smokes 10 or more cigarettes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-Young Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyoung-Ah Kim, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Un Jip Kim, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soo Kyung Kim, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyun Tae Park, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

